Primary myelofibrosis (PMF) is characterized by the clonal expansion of megakaryocytes and myeloid cells from stem cells with abnormal cytokine expression, resulting in bone marrow fibrosis, angiogenesis, and osteosclerosis. The use of next-generation sequencing revealed that both genetic and epigenetic changes are important in the pathogenesis of PMF. Several epigenetic regulator genes, including TET2, the polycomb-related gene ASXL1, and the polycomb-group gene EZH2, have been found to be targeted by somatic gene mutations in PMF patients. Among these, loss of Ezh2 has been demonstrated to disrupt the function of the polycomb repressive complex 2, promoting the development of JAK2 V617F -induced myelofibrosis in mice. In this analysis, we highlight the role of PRC dysfunction in the pathogenesis of PMF.
Keyphrases
- copy number
- genome wide
- bone marrow
- dna methylation
- stem cells
- end stage renal disease
- genome wide identification
- gene expression
- ejection fraction
- long non coding rna
- poor prognosis
- newly diagnosed
- endothelial cells
- chronic kidney disease
- mesenchymal stem cells
- prognostic factors
- long noncoding rna
- high glucose
- transcription factor
- acute myeloid leukemia
- dendritic cells
- single cell
- high fat diet induced
- genome wide analysis
- cancer therapy
- cell therapy
- insulin resistance
- binding protein